The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
So the recent price action of late was for the fundraiser ! , reaction to today’s RNS says it all. “primary aim of helping patients.", this is a charity not a business, sub 70p incoming.
The approval of the trial protocol, and in particular the data capture and dosage control methodologies, has also led to further exploration of the potential use of the protocol to treat other conditions. Discussions are ongoing with a healthcare provider about a novel application for the protocol.
Be interested to know what those other conditions are and if this will create a material delay to the planned commencement of the main CANPAIN trial?
And this:
On 8 March 2024, the Group disposed of its investment in Harley Street (CPC) Limited for a consideration of £500,000 payable over three years. At the time of the disposal, the only activity conducted by Harley Street (CPC) Limited was the operation of a CQC registered clinic. The assets relating to the CANPAIN Trial had been transferred to Celadon Property Co Limited during 2023.
On 31 May 2023, Celadon Property Co Limited acquired the remaining 42.5% shareholding for £1
Did not seen an RNS for this?
Agreement. At 31 December 2023, £10k of the Facility had been drawn
Good to know - so have at least 9m including recent raise, unless they used some of the facility post year end
The prospect of the CANPAIN protocol being used in other jurisdictions, as well as for the treatment of other conditions, further demonstrates the vast potential that cannabis-based medicines offer Celadon, national health providers, and most importantly, patients.
How do CEL benefit from farming out their protocol?
Some questions:
The Group has started to deliver on its commercial Supply Agreements and has several additional customer contracts in negotiation demonstrating the continuing and increasing demand for high-quality UK grown cannabis products.
Well what year will they be getting their products, if Phase I is meeting existing contracts and Phase II will complete in 2025 and will be used for the 24m contract?
Would take a look at GENE and OCTB before reaching that conclusion.
Looks more like a 3.5% dilution to me. How many more times does he have to tap shareholders before he makes money?
Looks pretty bullish to me, anyone any ideas why this would be the case?
It is expected that First Admission will occur on or around 15 May 2024, with the remaining 714,286 shares being admitted in three instalments on 10 June, 15 July and 12 August 2024
Yeah I think we'll get an update from the company this week. I'm hoping that pushes us past the 120 range...
Yes, it has slipped almost 20%. The company needs some real news.
Could do with something or else we will end up slipping back to 80. Seems to be trending between 80-120 in the absence of any news.
Hoping we'll see some good news on here next week...
Yeah hopefully we see a nice end to the week
Nice to see some big buys this morning
Agreed.
This is my post of March 2023:
I have followed this share a while and attended the AGM.
DYOR but my notes from that AGM were that:
The current facility can produce product for 50,000 patients.
In the Uk alone there are 3 million patients who may be eligible for a cannabiniod remedy.
At full capacity the facility can grow 10 to 15 tonnes of product a year and that could equal £90m annual revenue.
Companies in this space (pharmaceutical not cannabinoid - don't make that mistake ) trade on typically greater than 14* ebitda.
Factor in the 63m share float and you get the picture.
I see no reason why this therefore cannot emulate GWP and the management have demonstrated that they can execute.
Agreed on the consolidation. I just tucked away a few more yesterday. Really think this could be an AIM unicorn...
Nice to see the shares consolidating at this level. Expecting another leg up soon.
Soon as the market let you buy shares, I'm really expecting this to start moving quickly
Full ask being hit again... This has to move up soon...
Looks like we are in for a big drive north in the share price. Great to see the company getting huge coverage from the media.
Https://www.itv.com/news/2024-04-22/ive-sold-my-house-to-pay-for-my-daughters-medical-cannabis
Waw Celadon on itv news...